PharmaCyte Biotech Inc
PMCB1.010USD
+0.010+1.00%
Market hours （ET）Quotes delayed by 15 min
6.97MMarket Cap
1.09P/E TTM
More Details of PharmaCyte Biotech Inc Company
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Company Info
Ticker SymbolPMCB
Company namePharmaCyte Biotech Inc
IPO dateSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 11
Address3960 Howard Hughes Parkway, Suite 500
CityLAS VEGAS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code89169
Phone19175952850
Websitehttps://pharmacyte.com/
Ticker SymbolPMCB
IPO dateSep 11, 2003
CEOMr. Joshua N. (Josh) Silverman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, May 13
Updated: Tue, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
7.68%
The Vanguard Group, Inc.
2.83%
Geode Capital Management, L.L.C.
2.02%
Equitec Proprietary Markets, LLC
1.21%
Asher (Daniel B)
1.21%
Other
85.05%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
7.68%
The Vanguard Group, Inc.
2.83%
Geode Capital Management, L.L.C.
2.02%
Equitec Proprietary Markets, LLC
1.21%
Asher (Daniel B)
1.21%
Other
85.05%
Shareholder Types
Shareholders
Proportion
Corporation
7.68%
Investment Advisor
4.57%
Individual Investor
2.85%
Investment Advisor/Hedge Fund
2.60%
Hedge Fund
1.14%
Bank and Trust
0.05%
Other
81.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
66
1.30M
18.90%
-536.38K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
2023Q1
79
7.49M
40.43%
+256.98K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Intracoastal Capital, L.L.C.
527.38K
7.68%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
194.52K
2.83%
+2.13K
+1.11%
Mar 31, 2025
Geode Capital Management, L.L.C.
138.94K
2.02%
-25.80K
-15.66%
Mar 31, 2025
Equitec Proprietary Markets, LLC
82.73K
1.21%
--
--
Mar 31, 2025
Asher (Daniel B)
82.73K
1.21%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.73%
--
--
Feb 01, 2025
Silverman (Joshua N.)
50.00K
0.73%
--
--
Feb 01, 2025
Renaissance Technologies LLC
49.50K
0.72%
+200.00
+0.41%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
25.50K
0.37%
-200.00
-0.78%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
20.30K
0.3%
-6.54K
-24.37%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
